<DOC>
	<DOCNO>NCT01007552</DOCNO>
	<brief_summary>To assess proposed therapy patient advance gallbladder biliary cancer .</brief_summary>
	<brief_title>A Study Gemcitabine , Capecitabine Bevacizumab Treat Cancer Gall Bladder Bile Ducts</brief_title>
	<detailed_description>The primary objective study assess progression free survival propose therapy patient locally advance metastatic adenocarcinoma gallbladder biliary duct .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patients must histologically cytologically confirm gallbladder biliary tract adenocarcinoma unresectable metastatic , metastatic adenocarcinoma radiologically confirm gallbladder biliary origin . No prior systemic therapy metastatic disease . Prior adjuvant therapy permit complete 6months ago . Age ≥ 18 year . Because dose adverse event data currently available use bevacizumab combination gemcitabine patient 18 year age , child exclude study , eligible future pediatric phase 1 combination trial . ECOG performance status 0 1 . Life expectancy &gt; 3 month . Patients must normal organ marrow function define : leukocyte ≥ 3,000/microL absolute neutrophil count ≥ 1,500/microL platelet ≥ 1OO , OOO/microL total bilirubin ≤ 2 mg/dl AST ALT ≤ 5 time upper limit normal ( UNL ) subject document liver metastasis ; ≤ 2.5 time UNL subject without evidence liver metastasis . creatinine &lt; 1.5 mg/dL 24 hour urine creatinine clearance &gt; 50 ml/min . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Signed , write informed consent document . Patient must measurable disease Subjects meeting follow criterion ineligible study entry : Compromised renal hepatic function . Screening clinical laboratory value INR ≥ 1.5 ( except subject receive fulldose warfarin ) Hemoglobin &lt; 9 gm/dL ( may transfuse receive epoetin alfa ( e.g. , Epogen @ ) maintain exceed level ) . Bevacizumab risk factor : History serious systemic disease , include uncontrolled hypertension ( blood pressure great 160/110 mmHg medication ) , prior history hypertensive crisis hypertensive encephalopathy , unstable angina , New York Heart Association ( NYHA ) Grade II great congestive heart failure , unstable symptomatic arrhythmia require medication ( subject chronic atrial arrhythmia , i.e. , atrial fibrillation paroxysmal supraventricular tachycardia eligible ) , clinically significant peripheral vascular disease ( Grade II great ) . Presence central nervous system brain metastasis . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 , anticipation need major surgical procedure course study ; fine needle aspiration core biopsy within 7 day prior Day O. Pregnancy ( positive pregnancy test ) lactation . 24 hour urine creatinine clearance &lt; 50 ml/min urine protein/creatinine ratio great equal 1.0 screening . Serious , nonhealing wound , ulcer , bone fracture . Evidence bleed diathesis coagu1opathy . Recent ( less equal six month ) arterial thromboembolic event , include transient ischemic attack ( TIA ) , cerebrovascular accident ( CVA ) , unstable angina , myocardial infarction ( MI ) . Inability comply study and/or followup procedure . Patients know duodenal gastric wall involvement exclude . Patients suspect involvement stomach duodenum screen endoscopy exclude prior therapy . Patients esophageal gastric varix . Patients recent hemoptysis ( within 1 week ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Biliary Duct Cancer</keyword>
	<keyword>Cancer Gallbladder</keyword>
	<keyword>Adenocarcinoma Gall Bladder</keyword>
	<keyword>Adenocarcinoma Biliary Ducts</keyword>
	<keyword>Cholangiocarcinoma</keyword>
	<keyword>Extrahepatic cholangiocarcinoma</keyword>
</DOC>